[Comment] Is there a FUTURE for urodynamic testing in refractory overactive bladder syndrome?
Overactive bladder is a chronic condition that affects 10–45% of women worldwide;1 however, more than half of women discontinue conservative and medical treatment.2,3 Predicting which women are better served by more invasive, third-line treatments, such as intradetrusor botulinum toxin A (BoNT-A) or sacral neuromodulation, has been elusive. Urodynamic studies have been used to better assess the cause of lower urinary tract symptoms. Expert societies, such as the European Association of Urology and the Canadian Urology Association, recommend conducting urodynamic studies in the event of treatments that did not work, when the diagnosis of overactive bladder is unclear, or if the choice of invasive treatments might change.
Overactive bladder is a chronic condition that affects 10–45% of women worldwide;1 however, more than half of women discontinue conservative and medical treatment.2,3 Predicting which women are better served by more invasive, third-line treatments, such as intradetrusor botulinum toxin A (BoNT-A) or sacral neuromodulation, has been elusive. Urodynamic studies have been used to better assess the cause of lower urinary tract symptoms. Expert societies, such as the European Association of Urology and the Canadian Urology Association, recommend conducting urodynamic studies in the event of treatments that did not work, when the diagnosis of overactive bladder is unclear, or if the choice of invasive treatments might change.
